Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 51,004 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $22.45, for a total value of $1,145,039.80. Following the completion of the sale, the insider directly owned 237,688 shares of the company’s stock, valued at approximately $5,336,095.60. The trade was a 17.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Thursday, July 2nd, Francis Lo sold 44,838 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.59, for a total value of $1,012,890.42.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.49, for a total value of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.07, for a total value of $340,039.48.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock opened at $21.50 on Tuesday. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $22.80. The business’s fifty day moving average is $16.24 and its 200 day moving average is $15.90. The stock has a market capitalization of $3.44 billion, a PE ratio of -65.15 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. As a group, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ADPT has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. JPMorgan Chase & Co. cut their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Guggenheim boosted their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Morgan Stanley reduced their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. increased its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at $51,000. Finally, Strive Financial Group LLC purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth $52,000. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.